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There is no cure for osteogenesis imperfecta (OI), and current treatments can only partially correct the bone
phenotype. Stem cell therapy holds potential to improve bone quality and quantity in OI. Here, we conduct a
systematic review and meta-analysis of published studies to investigate the efficacy of stem cell therapy to rescue
bone brittleness in mouse models of OI. Identified studies included bone marrow, mesenchymal stem cells, and
human fetal stem cells. Effect size of fracture incidence, maximum load, stiffness, cortical thickness, bone volume
fraction, and raw engraftment rates were pooled in a random-effects meta-analysis. Cell type, cell number, in
jection route, mouse age, irradiation, anatomical bone, and follow up time were considered as moderators. It was
not possible to investigate further parameters due to the lack of standards of investigation between the studies.
Despite the use of oim mice in the majority of the investigations considered and the lack of sham mice as control,
this study demonstrates the promising potential of stem cell therapy to reduce fractures in OI. Although their low
engraftment, cell therapy in mouse models of OI had a beneficial effect on maximum load, but not on stiffness,
cortical thickness and bone volume. These parameters all depend on bone geometry and do not inform on its
material properties. Being bone fractures the primary symptom of OI, there is a critical need to measure the
fracture toughness of OI bone treated with stem cells to assess the actual efficacy of the treatment to rescue OI
bone brittleness.

1. Introduction
Osteogenesis imperfecta (OI) is a genetic disorder of collagen and
collagen-associated genes characterized by bone fragility and skeletal
deformities. OI affects 1 in 10,000 births, and both genders equally (Van
Dijk and Sillence, 2014). It is an inherited dysplasia with prenatal onset
that has been categorized into 21 genetically distinct types (Rossi et al.,
2019). Types of OI differ in modes of inheritance, ranging from domi
nant, recessive, and X-linked and result in a range of phenotypic severity
and symptoms (Kang et al., 2017). OI also ranges in its clinical mani
festations, from mild symptoms with normal lifespans to perinatal
lethality (Huber, 2007). Most OI cases result from mutations affecting
the genes COL1A1 and COL1A2 encoding for the α1 and α2 chains that
constitute type I collagen. Collagen type I is the most abundant form of
collagen in the body and is the major protein found in bone, tendon,
ligament, skin, sclera, cornea, and blood vessels. It is composed of two
identical α1 polypeptide chains and one distinct α2 polypeptide.

Mutations in the COL1A1 and COL1A2 genes can either affect the amino
acid sequence, thus resulting in abnormal collagen production, or cause
haploinsufficiency, which prevents polypeptide chains from forming.
Mutant procollagen chains unable to be incorporated into heterotrimers
are either degraded via proteasome, eliminated through autophagy,
degraded through alternate pathways, or secreted into the extracellular
matrix. These pathways result in bone fragility, the hallmark of OI
(Forlino et al., 2011; El-Gazzar and Högler, 2021).
There is no cure for OI. Current available treatment options include
pharmaceuticals, physiotherapy, rehabilitation, and surgery (Milling
ton-Ward et al., 2005). Bisphosphonates have been the predominant
therapeutic for the OI population and act by reducing osteoclastic ac
tivity. While bisphosphonates have demonstrated beneficial effects in
increasing bone mineral density and improving mobility (Roldán et al.,
1999; Biggin and Munns, 2017; Shi et al., 2016), the effects of
bisphosphonates on fracture rate remain unclear. Clinical meta-analysis
studies have shown that bisphosphonates did not significantly reduce
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the proportion of people with OI experiencing fracture compared to
controls (OI with no treatment, OI with placebo and OI with other
comparator interventions) (Hald et al., 2015; Dwan et al., 2016).
Furthermore, bisphosphonates have been shown to cause other potential
adverse skeletal consequences, including delayed tooth development
and delayed healing of osteotomy sites (Roldán et al., 1999; Biggin and
Munns, 2017; Shi et al., 2016). Thus, as bisphosphonates do not address
the issue of poor bone quality in OI, questions remain regarding the
ability of this treatment to improve bone toughness as well as its efficacy
with long-term treatment in growing children with OI (Biggin and
Munns, 2017). Therefore, a need remains for treatment strategies that
tackle the underlying genetic defect to improve OI bone quality.
Stem cell therapy may represent a viable solution for OI as it holds
the potential to correct the bone phenotype by utilizing genetically
healthy cells early in their development to remodel OI bone. Mesen
chymal stem cells (MSCs) are mononuclear progenitor stem cells with
the ability to self-renew. They have the capacity to differentiate into
osteoblasts (OB), chondrocytes, myocytes, adipocytes, and neurons
(Rohban and Pieber, 2017). These cells can be found in the bone
marrow, umbilical cord, umbilical cord blood, placenta, amniotic fluid,
and adipose tissue (Rohban and Pieber, 2017). Notably, MSCs have a
homing ability, as they can migrate to injured sites, differentiate into
local components, and secrete chemokines, cytokines, and growth fac
tors to aid in tissue regeneration (Zhang et al., 2016). Additionally,
MSCs have immunosuppressive, anti-apoptotic, and anti-inflammatory
properties (Ranzoni et al., 2016). These qualities make MSCs good
candidates for clinical transplant therapies. Commonly investigated
sources of MSCs include bone marrow-derived mesenchymal stem cells
(BMSCs or bone marrow stromal cells) and human fetal mesenchymal
stem cells. Cell therapy for the treatment of OI aims to overcome the
consequences of dominant-negative OI mutations by introducing nondifferentiated cell progenitors with the possibility that they will suc
cessfully engraft to the bone, undergo osteogenic differentiation, and
participate in bone modeling and remodeling, replacing mutant
endogenous cells. Recent findings suggest that transplanted cell pro
genitors are able to contribute to bone remodeling through the release of
paracrine factors of bioactive molecules, proteins and RNAs that can
deliver signals for intercellular communication (Phinney et al., 2015).
In 1998, Pereira et al. (1998) were the first to investigate the po
tential ability of wild type (WT) MSCs to rescue the fragile bone
phenotype of OI mice. Primary adherent MSCs were infused via intra
peritoneal injection to OI-transgenic mice expressing the collage type I
mini gene. Mice displayed a small but significant increase in mineral
content and bone collagen content one month following treatment.
Donor cell DNA was detected in the bone, bone marrow, cartilage, and
lungs 2.5 months after infusions. An experiment, in which male MSCs
were infused into female OI-transgenic mice, utilized fluorescence insitu hybridization assays for the Y chromosome and showed that at
2.5 months following infusions donor cells accounted for 4–19% of
fibroblast-like cells in the primary cultures of lung, calvaria, cartilage,
long bone, tail, and skin tissues (Pereira et al., 1998). This initial study
demonstrated the possibility of using cell progenitors for the treatment
of OI.
Following the results of this and other pre-clinical models showing
the potential of MSCs to correct collagen-related disorders, Horwitz
et al. (1999) investigated allogeneic bone marrow transplantation
(BMT) in OI children. Five patients were intravenously infused with
unmanipulated bone marrow from human leukocyte antigen matched or
single-antigen mismatched siblings after ablative conditioning therapy
(Horwitz et al., 1999). Engraftment was assessed in two children about
12–14 weeks following BMT, and showed only 1.5–2.0% donor-derived
OB (Horwitz et al., 1999). Increased growth acceleration and total body
bone mineral content (TB-BMC) was reported for three children in the
six months following transplantation compared to two non-transplanted
OI controls. Growth rates slowed or plateaued with extended follow up
time up to six months following transplantation, however bone mineral

content continued to increase (Horwitz et al., 2001). A decrease in
fracture rate was observed up to 12 months after BMT (Horwitz et al.,
1999). Due to unsustained improvements, patients then underwent two
rounds of infusions with cultured, retroviral vector gene-marked BMSCs
from the prior donors 18–34 months after BMT. Between four and six
weeks after infusions, five out of the six patients showed engraftment in
bone among other tissues. Over the six months following infusions, these
five patients displayed increased growth velocities, ranging from 60 to
90% of the predicted median compared to negligible growth in the six
months preceding therapy. However, only one patient showed increased
TB-BMC three months post therapy (Horwitz et al., 2002). These case
studies show that injected MSCs are able to engraft in the bone, marrow
stroma, and skin without preparative chemotherapy and not elicit severe
immune responses. Initially the cells were able to produce clinically
measurable benefits; though it is unclear why these outcomes were
short-lived. Additionally, confirmation of engraftment in these studies
was not clear as OB were not identified so donor cells may have been
hematopoietic in origin (Horwitz et al., 1999, 2001, 2002). Finally,
despite increased amount of normal collagen fibers deposited by these
cells in the bones (Horwitz et al., 1999), there was no evidence that cells
were capable to produce a healthy matrix.
These studies set the go for further research to continue investigating
the effects of stem cell therapies on OI bone in the following decades.
Different stem cell types, cell dosages, routes of delivery, age at injection
and cell culture conditions are just some of the parameters under
investigation in an attempt to rescue OI bone fragility. This metaanalysis aimed to define the effects of stem cell therapy on the me
chanical, structural and compositional properties of the OI bone. This
analysis reports the current knowledge on the effects of stem cell therapy
on bone brittleness in OI and emphasizes gaps that need further inves
tigation for a comprehensive understanding of the effect of stem cell
treatment on OI bone quality and fragility, and for ensuring the effective
translation of stem cell therapy for OI from preclinical to clinical setting.
2. Meta-analysis methods
The Preferred Reporting Items for Systematic Reviews and Metaanalyses statement was used to guide our methods. A literature search
was conducted using databases including PubMed, Embase, Science
Direct, SciFinder, and Science.gov, from their inception dates to April
2021 (Fig. 1). Keywords used for search included (Osteogenesis Imper
fecta) AND (Stem cell OR Stromal cell).
2.1. Eligibility criteria
2.1.1. Study types
Inclusion criteria included controlled trials utilizing stem cell ther
apy for the treatment of mouse models of OI. Clinical trials, case reports,
and in vitro studies were excluded. Reviews, editorials, comments, and
conference articles were excluded.
2.1.2. Mouse types
Studies using any mouse model of osteogenesis imperfecta were
included. Studies were excluded if the untreated OI mouse model did not
demonstrate phenotypic bone fragility in their control OI group.
2.1.3. Intervention types
Studies using stem cell therapy, including human- or mice-derived
bone marrow or stem cells compared with a control group were
considered, as well as those using retrovirally transduced reporter genes
for cell tracking purposes. Studies using genetically engineered stem
cells were instead excluded.
2.1.4. Outcome types
Bone compositional, structural, mechanical properties were
reviewed. This analysis includes the outcomes common between three
2
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investigated these properties. Biological properties common to the
selected studies, such as cell engraftment (expressed as the raw per
centage of engrafted transplanted cells to total cells) and fracture inci
dence, calculated as the total number of fractured long bones over the
total number of long bones considered, were also considered for this
meta-analysis.
2.2. Data extraction
Titles and abstracts and then the full-text articles were screened ac
cording to the eligibility criteria. Studies satisfying the inclusion and
exclusion criteria were enrolled in the meta-analysis. The mean results,
standard deviations pertaining to the results, and number of animals of
experimental and control groups were extracted to calculate effect size,
which represented the magnitude of the observation. Standardized
mean difference (SMD), mean difference (MD), and risk ratio (RR)
served as effect size measurements for the variables as appropriate.
Other information regarding mouse model, cell type, route of delivery,
age of treatment, cell dosage, and follow up times were incorporated in
the database (Table 1). In studies using different follow up time points
for data measurement, the last time point was considered for analysis.
Corresponding authors were contacted in the case of missing data. When
original study data was not available, GraphClick software was used to
approximate data from bar graphs.
2.3. Study quality assessment
Due to the nature of these basic science research studies, that were
principally to evaluate effects of transplantation using different read
outs, a formal quality assessment was not applicable. However, study
characteristics including choice of controls, blinding, biases, and base
line characteristics are reviewed in the discussion.
2.4. Statistical analysis

Fig. 1. Study flow diagram of the selection process. A total of 2151 studies
were retrieved from the literature review. Abstracts and titles were reviewed
and excluded when not matching eligibility criteria. Duplicates were also
excluded. 98 full texts were reviewed with clinical trials, review articles, and
studies using non-mouse animal models then being excluded. Subsequently 26
full text articles were considered with 10 studies meeting all inclusion criteria.

Data review and analyses were performed using Review Manager 5.3
software by the Cochrane Collaboration (Review Manager Web (Rev
Man Web), 2019) and SPSS Statistics (IBM Corp., Armonk, N.Y., USA)
(Field and Raphael, 2005). SMD, MD, and RR were used as a measure of
effect size in a random effects model. Each effect was expressed as a 95%
confidence interval (CI). The effect size was considered significant if the
relative 95% CI did not include 0. Risk ratios lower than one signified a
decrease in risk. Heterogeneity was considered significant at p < 0.10
(Green et al., 2008). Inconsistency was estimated using the I2 statistic,
describing the percentage of total variation across studies that is due to

or more studies (Green et al., 2008; Hooijmans et al., 2014): cortical
thickness, bone volume fraction (BV/TV), stiffness, and maximum load.
The effects of other compositional, structural, and mechanical parame
ters were not analyzed due to low number of studies (two or less) that

Table 1
Study characteristics of stem cells injected in mouse models of OI. iSCP = induced single cell progenitors; MSC = mesenchymal stem cells; BM = bone marrow; fSC =
fetal stem cells; BMSC = bone marrow stromal cells; fMSC = fetal mesenchymal stem cells; NA-BMC = non-adherent bone marrow cells, e-CSC = early chorionic stem
cells, AFSC = amniotic fluid stem cells; IUT = intrauterine transplantation; IP = intraperitoneal.
Study

Cell type

Number of cells
(×e6)

Route of delivery

Irradiation
(cGv)

Mouse
type

Age (wk) at
injection

Follow up time
(wk)

Li et al. (2007)

B6C3Fe iSCP

0.05

350

oim/oim

Neonates

4

Guillot et al. (2008)
Panaroni et al.
(2009)
Vanleene et al.
(2011)
Li et al. (2010)
Jones et al. (2012)
Otsuru et al. (2012)

Human fetal MSC
CMV/eGFP CD-1 BM

1
5

Superficial temporal
vein
IUT embryonic
IUT embryonic

None
None

oim/oim
BrtlIV

Fetus
Fetus

4, 8, 12
8

Human fSC

1

IUT embryonic

None

oim/oim

Fetus

8

WT BMSC
Human fMSC
H2K-GFP NA-BMC,
MSC
Human fetal e-CSC
Human AFSC

1
1
2

Femur medullary space
IP
Intradermal tail vein

350
None
1125

oim/oim
oim/oim
oim/oim

4
Neonates
4–6

6
8
3

1
1

IP
IP

None
None

oim/oim
oim/oim

Neonates
Neonates

8
8

SMA9/Col2.3GFP
BMSC

1

Femur medullary space

900

oim/oim

8–10

12

Jones et al. (2014)
Ranzoni et al.
(2016)
Sinder et al. (2020)

3
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2.09, 95% confidence interval = − 0.45-4.64, p = 0.11, I2 = 96).

heterogeneity rather than chance. Values of 25, 50, and 75% were
considered low, moderate, and high inconsistency (Higgins et al., 2003).
Categorical and continuous moderator analyses were conducted in
order to examine the impact of study factors on the results. Factors
including mouse model, cell type, route of delivery, age at time of
treatment, cell dosage, time at follow up, and experimental anatomical
bone type were analyzed when appropriate and with sufficient study
numbers.

3.3. Structural properties
No significant effect of stem cell therapy was shown on the structural
properties here analyzed. Both cortical thickness and BV/TV showed
trends of a beneficial effect but not statistical significance as their CIs
intersected 0 (SMD = 0.64, 95% confidence interval = − 0.85-2.12, p =
0.4, I2 = 90%; SMD = 1.38, 95% confidence interval = − 1.26-4.02, p =
0.31, I2 = 92%). Follow up time was shown to significantly, categori
cally moderate the effect of cell therapy on cortical thickness (categor
ical χ2 = 6.354, p = 0.042; continuous χ2 = 4.996, p = 0.172).

2.5. Publication bias within the meta-analysis
Funnel plots were created to visualize the potential of publication
bias with Meta-Essentials for Microsoft Excel (Suurmond et al., 2017).
Tests for funnel plot asymmetry were not included, as recommended by
Stern et al. (Sterne et al., 2011) for the analyses of less than 10 studies.

3.4. Cell engraftment
Five of the 10 included studies reported engraftment rate in terms of
percentage of engrafted donor cells to total cell number, measured
through either histological section (Panaroni et al., 2009; Otsuru et al.,
2012) or quantitative PCR (Li et al., 2007; Vanleene et al., 2011; Jones
et al., 2012) cell counting of green fluorescent protein (GFP) positive
cells/human cells on bone. A forest plot in Fig. 2 shows the low and
variable raw engraftment percentages (the mean difference between
engraftment rates of transplanted and non-transplanted mice).

3. Results
3.1. Study selection
The literature search identified 2151 articles, 10 of which were
eligible for this review (Fig. 1) (Ranzoni et al., 2016; Li et al., 2007;
Guillot et al., 2008; Panaroni et al., 2009; Li et al., 2010; Vanleene et al.,
2011; Jones et al., 2012; Otsuru et al., 2012; Jones et al., 2014; Sinder
et al., 2020). All selected studies were in English. Characteristics of
included studies are depicted in Table 1. The studies meeting all criteria
and included in the meta-analysis used oim/oim (B6C3Fe-a/aCol1a2oim/
oim
) and/or BrtlIV/+ (Col1a1tm1.1Jcm/Col1a1+) mouse models of OI. Oim
mice have a mutation in the gene encoding the α2 chain of type I pro
collagen, preventing the proper assembly of collagen propeptides. This
mouse model is representative of moderate to severe forms of OI in its
heterozygotes and homozygotes forms, respectively (Saban et al., 1996;
Enderli et al., 2016). BrtlIV/+ is a knock-in mouse with a classical
glycine substitution in type 1 collagen exhibiting a phenotype resem
bling moderately severe and lethal OI (Enderli et al., 2016; Forlino et al.,
1999). The oim/oim and BrtlIV/+ mice treated with cell progenitors
received intrauterine transplantation, intraperitoneal, tail vein, tempo
ral vein, or local femoral injections. At the time of injection, mice ranged
from neonates to 10-week-old mice with follow up durations ranging
from four weeks to three months. Within the ten included studies, two
investigated BMSCs (Li et al., 2010; Sinder et al., 2020), one bone
marrow (Panaroni et al., 2009), two used derivatives of BMSCs (Li et al.,
2007; Otsuru et al., 2012), four studied types of human fetal stem cells
(Guillot et al., 2007, 2008; Vanleene et al., 2011; Jones et al., 2012;
Jones et al., 2014), and one amniotic mesenchymal stem cells (Ranzoni
et al., 2016). Though these cell treatments exhibit varying levels of
stemness, we will refer to them as stem cells in our discussion. Number
of cells delivered and amount of irradiation also varied across studies.
Only one study (Millard et al., 2015) was excluded from this metaanalysis because control oim mice treated with phosphate buffered sa
line intrauterine transplantation (PBS-IUT) did not exhibit the pheno
typic fragility of the OI bone. Most of the selected studies used original
OI mice, and not sham treated mice, as controls (Ranzoni et al., 2016; Li
et al., 2007; Guillot et al., 2008; Panaroni et al., 2009; Vanleene, 2011;
Jones et al., 2012; Jones et al., 2014). Multiple parameters were
investigated within this meta-analysis to understand the efficacy of stem
cell therapy on OI bone mechanical and structural properties (Fig. 2).

3.5. Fracture incidence
The fracture incidence was shown to be significantly decreased with
stem cell therapy (RR = 0.27, 95% confidence interval = 0.19–0.38, p <
0.00001, I2 = 0%).
3.6. Heterogeneity
High heterogeneity and inconsistency were found in all outcomes
investigated except in fracture incidence. Random effects analysis was
utilized to partially address this heterogeneity as well as decrease risk of
erroneous estimates.
4. Discussion
This meta-analysis shows that stem cell therapy in mouse models of
OI has a significant beneficial effect in decreasing fracture incidence and
increasing maximum load, despite low rates of cell engraftment.
Maximum load was shown to be influenced by anatomical bone (tibia vs.
femur). This is not surprising as maximum load depends on the geometry
of the bone, and femur and tibia greatly differ in their shape despite
being both long bones. Cell therapy was shown to not have an effect on
bone stiffness, cortical thickness, or BV/TV. These findings predomi
nantly coincide with the results from clinical trials (Horwitz et al., 2001;
Amin and Shazly, 2014; Le Blanc et al., 2005; Götherström et al., 2014).
The low cell engraftment in OI-stem cell treated bone has been
demonstrated in numerous studies using animal models and is in
agreement with the few existing human clinical trials (Pereira et al.,
1998; Horwitz et al., 1999, 2001, 2002; Li et al., 2007; Guillot et al.,
2008; Panaroni et al., 2009; Vanleene et al., 2011; Otsuru et al., 2012).
The use of different cell types, dosages, delivery routes, and follow up
times resulted in low but variable engraftment rates both within and
between studies (from 0.3% to 28% in a given bone chip) (Li et al.,
2007). Regardless the variety of parameters considered in these studies,
vast and consistent improvements in the engraftment (i.e. the percent
age of engrafted transplanted cells to total cells) have not been shown.
Among the considered studies, only Guillot et al. (Guillot et al., 2008)
studied the engrafted cells longitudinally using qRT-PCR at 1, 2, 4, 8,
and 12 weeks. They reported engraftment of 5% at week one, with levels
slightly decreasing over time and then stabilizing around 4% from weeks
four to 12. Despite the low engraftment rate, stem cell therapy in mouse
models of OI has been shown to decrease their bone fracture incidence,

3.2. Mechanical properties
The meta-analysis showed that stem cell therapy had a significant
beneficial effect on increasing maximum load (SMD = 2.36, 95% con
fidence interval = 0.41–4.31, p = 0.02, I2 = 94%). Moderator analyses
showed anatomical bone (categorical, χ2 = 5.014, p = 0.025) and follow
up time (continuous, χ2 = 9.855, p = 0.043) to significantly moderate
these results. Cell therapy had no significant effect on stiffness (SMD =
4
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Fig. 2. Forest plots showing the effect size of stem cell therapy on mouse models of OI. Compared with a control group, A) standardized mean difference (SMD)
of maximum load, B) SMD of stiffness, C) SMD of BV/TV, D) SMD of cortical thickness, E) mean difference (MD) of raw engraftment percentages, F) risk ratio (RR) of
fracture incidence. Studies considered for each analysis are presented on the left side and in the forest plot their weight is represented with a square and with a line
representing their 95% confidence interval (CI). Black diamonds in the forest plot represent the total effect size, with the width representing its 95% CI. Diamonds
falling completely to the right side of the graph, favoring cell therapy, show a significant effect. The diamond representing RR of fracture incidence is shown to be
significant as the risk is less than 1, thus representing a decrease in fracture incidence. Each forest plot is shown with its funnel plot, a scatter plot of the study effect
size against its standard error. These plots are used for the assessment of potential publication bias, with asymmetry within the plots resulting from possible nonreporting biases, poor methodological quality, or true heterogeneity. Fracture incidence does not include error bars as standard risk ratio does not include stan
dard deviations. Chi2 measures heterogeneity and I2 inconsistency. MSC = mesenchymal stem cells; NA-BMC = non-adherent bone marrow cells.
5
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as demonstrated in this meta-analysis. Substantial improvements are not
shown in most other investigated parameters, such as structural and
mechanical measurements of the cortical bone, which surprisingly are
actually neglecting to analyze the bone resistance to fracture (or
toughness) of the stem cell treated bone to quantify changes in OI bone
brittleness with therapy. Indeed, only a few studies examined
improvement in OI mouse bone quality after stem cell treatment. These
studies mostly considered oim mice, and all but three, which used the
contralateral leg of the same mouse (Li et al., 2010; Sinder et al., 2020)
or PBS-injected tail vein (Otsuru et al., 2012) as control, compared re
sults from stem cell treated OI mice to naïve OI mice as controls, and not
to sham operated OI mice, thus highlighting the need of further inves
tigation in the field. These collective results led us to three conclusions:
(1) the current laboratory strategies are not completely adequate in
identifying all possible beneficial effects of stem cell therapy on OI
mouse bone brittleness; (2) the use of different mouse models of OI, as
well as the use of original mice and shams as control, are needed to fully
comprehend the effect of stem cell treatment on OI bone quality and its
brittleness; and (3) the mechanisms of action of stem cells to enhance
properties of OI bone is still unclear and may be independent from cell
engraftment.
Regarding the adoption of adequate laboratory strategies to identify
the beneficial effects of stem cell therapy on OI bone fragility, this metaanalysis suggests the methodologies and outcomes investigated thus far
are not completely sufficient for analyzing the total effect of the treat
ment. An extremely important aspect of bone not yet been studied
widely is the proper assessment of the mechanical, structural, and
compositional properties of bone after stem cell therapy in order to fully
determine improvements of this treatment for OI bone. Bone fragility is
the primary symptom of OI, thus bone from OI mice treated with stem
cells must be tested for their brittleness to determine the efficacy of
treatment. To date, the most accurate measure of bone fragility is
determined by assessing its fracture toughness (Ritchie, 2011; Inzana
et al., 2013). Methodologies have been developed for testing fracture
toughness in mouse bone (Ritchie et al., 2008; Carriero et al., 2014a,
2014b; Rodriguez Florez et al., 2014) and they have successfully been
applied to investigate bone toughness in oim mice (Carriero et al., 2014c;
Docaj et al., 2020; Docaj and Carriero, 2020) as well as in other mouse
strains (Carriero et al., 2014d; Miller et al., 2017). Fracture toughness
informs on the material properties of the bone to resist crack propaga
tion – thus there is a critical need to make sure OI treated bone has
increased fracture toughness in order to reduce its fragility. Stiffness and
maximum load determined from the load-displacement curve highly
depend on both material properties and geometry of the bone consid
ered. Thus, these parameters do not appropriately inform on the bone
resistance to crack propagation. Bone strength from the stress-strain
curve should also be tested to inform on the properties of the bone
material to resist deformations. Because microcracks form in regions of
high strains, full field strain distributions on the OI mouse bone treated
with stem cells, as those acquired on other mouse models (Carriero et al.,
2021; Javaheri et al., 2018; Carriero et al., 2018; Poulet et al., 2016;
Javaheri et al., 2015; Carriero et al., 2014e), can inform on the ability of
the treated bone to sustain load without cracking.
On the structural properties, this study also reports on the lack of
investigation on the intracortical structure (organization and porosity
along the hierarchy). Intracortical porosity and lamellar structure are
important features to investigate in OI bones as fractures of the cortical
bone are typical for OI (Munoz et al., 2021). Bone fracture toughness is
influenced by both the amount and architecture of the intracortical ca
nals (Carriero et al., 2014b, 2014c; Yeni et al., 1997), and has been
suggested to depend on an organized lamellar structure (Carriero et al.,
2014c; Peterlik et al., 2006; Jepsen et al., 1996, 1997; Docaj and Car
riero, 2021). Furthermore, although cortical bone fragility is the major
clinical hallmark of OI, trabecular bone offers a high surface area, thus
providing exposed surface of bone for the transplanted cells to poten
tially engraft and (re)model. Because of this, it is expected that

trabecular bone would more rapidly exhibit the beneficial effects of stem
cell therapy than cortical bone, however this has not yet been thor
oughly investigated. This will also offer the possibility to study the in
fluence of stem cell therapy on endochondral ossification and bone
growth in OI. Similarly, compositional analyses of bone must be con
ducted at the tissue level to inspect the impact of stem cell therapy on OI
bone mineralization, non-collagenous proteins, water content, as well as
at the molecular and crystal level to assess collagen crosslinks and
relationship with the mineral, which may ultimately affect the bone
resistance to fracture.
Another important aspect to investigate is the mechanisms of action
of the transplanted stem cells: Where do cells engraft? Do they effec
tively reach bone? What do they differentiate into? And how do they
improve bone properties? The studies included in this meta-analysis
largely showed transplanted cells, though of differing types and routes
of transplantation, homed to bone and expressed OB genes (Li et al.,
2007; Guillot et al., 2008; Vanleene et al., 2011; Jones et al., 2014;
Ranzoni et al., 2016; Sinder et al., 2020). Li et al. (2007) described
transplanted single cell progenitors (SPCs) homed mostly to bones and
expressed OB-specific genes, later showing transplanted donor BMSCs
within newly formed bone localized with osteocalcin expressing cells,
suggesting OB contribution to bone formation (Li et al., 2010). Sinder
et al. (2020) showed that with local femoral BMSC transplantation,
donor progenitor cells differentiated into OB and osteocytes and
engrafted on the femur endosteal surface and within the matrix. Guillot
et al. (2008) showed transplanted cells clustered to areas of active bone
formation, Jones et al. (2014) found cells homing preferentially to the
long bone epiphyses, and Vanleene et al. (2011) and Ranzoni et al.
(2016) showed cells migrated to bone. These four studies also all found
these transplanted donor cells to be expressing OB genes (Ranzoni and
et al., 2016; Guillot et al., 2008; Vanleene et al., 2011; Jones et al.,
2014). Of note, Li et al. (2007), Ranzoni et al. (2016), and Guillot et al.
(2008) identified, to a lesser degree, transplanted donor cells in other
organs. For two studies included, histological observation of cells was
used to determine OB differentiation, rather than genetic profiling
(Panaroni et al., 2009; Otsuru et al., 2012). Controversially, another
study reported that donor bone marrow cells systemically injected into
OI mice do not become OB, but rather differentiate into the myeloid
lineage such as osteoclasts and osteal macrophages lining endosteal and
trabecular surfaces (Millard et al., 2015). Specifically, Millard et al.
(2015) investigated bone-associated donor cells following intrauterine
transplantation (IUT) of WT BM in oim mice. They reported that donor
cells did not contribute the OB lineage cells, but were associated with
osteoclasts or osteal macrophages (Millard et al., 2015). This study was
excluded from our meta-analysis because their control PBS-treated oim
mice did not show the expected bone fragility typical of OI bone. This
study used sham operated mice as control for investigating the effect of
stem cell treatment on OI bone quality. The authors described this un
characteristic lack of fractures in OI sham operated control bones as
possibly reflecting selection bias towards less fragile animals surviving
the process of IUT. This study thus further underlines the importance of
investigating the effect of stem-cell treatment in naïve OI mice controls
as well as in sham operated mice.
Most of the studies included in this meta-analysis compared un
treated oim mice to oim treated with stem cells+PBS, regardless differ
ences in the delivery route of cell therapy. Guillot et al. (2008), Panaroni
et al. (2009), Vanleene et al. (2011), Jones et al. (2012), Jones et al.
(2014), and Ranzoni et al. (2016), and Li et al. (2007) compared their
treated mice with naïve OI mice and did not use sham operated mice
receiving placebo. Otsuru et al. (2012) injected MSCs via tail vein into
oim mice and used PBS injected oim mice as their controls. The study of
Li et al. (2010) investigated multiple treatment groups with local in
jections, comparing left vs. right femurs with varying combinations of
cells, matrix, and PBS. Finally, Sinder et al. (2020) utilized local femoral
injections and compared oim cell treated femurs with their contralateral
leg as sham controls. Because of the complexity of the stem cell
6

L. Battle et al.

Bone Reports 15 (2021) 101108

treatments, particularly those involving irradiation and/or surgery, it is
advised that both naïve mice and sham operated controls be compared
to stem cell treated OI bone in order to fully evaluate the success of the
stem cell treatment to improve OI bone quality.
Similarly, there is a need to examine the effect of stem cell treatment
on the bone of different mouse models of OI. The studies meeting the
inclusion criteria in this meta-analysis mostly used the oim mouse
model, a murine model commercially available for decades and widely
used to understand OI disease and its bone fragility. Although oim mice
do not represent the genetic changes commonly observed in human OI,
they model bone phenotype of severe OI and are therefore relevant for
investigations of bone mechanics and the effect of therapies on bone
quality. Only one study meeting inclusion criteria used the BrtlV/+ mice
(Panaroni et al., 2009), a model that is instead still not publicly avail
able. The use of diverse mouse models of OI to examine the short- and
long-term effects of the engrafted cells on bone composition, structure
and mechanics is needed to fully understand how to utilize stem cell
treatment for rescuing bone fragility in OI.
Regarding the mechanism of action of stem cells, a new hypothesis in

the field, as summarized by Prockop (2017), suggests that transplanted
cells are able to produce beneficial effects in animal models and clinical
trials by secreting paracrine factors, cytokines, extracellular vesicles,
and other soluble factors which can deliver signals for intercellular
communication (Phinney et al., 2015; Otsuru et al., 2012; Valadi et al.,
2007). Yet, the mechanism behind their positive therapeutic effects is
not yet fully understood. The ability to identify and then overexpress the
responsible miRNA(s) or other trophic factors may lead to greater
therapeutic effects.
As we move forward, genetically modified stem cell treatments,
including gene insertion, deletion, and up-regulation, will need to be
further explored as they have shown recent promising findings. These
studies have built upon the knowledge gained from the aforementioned
studies while seeking discovery of additional biological and mechanical
improvements. Jones et al. (Jones et al., 2012) investigated the protein
CXCR4, shown to influence MSC migration to fracture site, and found
that up-regulation lead to increases in bone engraftment and improve
ments in bone mechanics. Recently, Liu et al. (2020, 2021) showed
promising mechanical and structural improvements in the treatment of

Fig. 3. Properties of bone health to be investigated to assess treatment efficacy. To assess the efficacy of stem cell therapy in bone, it is crucial to investigate
bone health in its totality, and thus structural, compositional, biological, and mechanical properties of bone should be examined in detail and considering the
relationship between them. Such a comprehensive and interrelated analysis of stem cell treated bone will reveal the mechanisms of stem cells in bone signaling and
(re)modeling, and their efficacy to rescue bone brittleness in osteogenesis imperfecta. This interdisciplinary approach to medicine will ultimately guide stem cell
therapy to improve bone quality and quantity in mice with brittle bone, and ultimately translate to clinical use to promote health in patients with osteo
genesis imperfecta.
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an OI type I mouse model with genetically modified adipose-derived
stem cells. They investigated genetic modifications with recombinant
mouse NELL1 protein and Nell1 gene as well as autologous COL1A1
gene modification (Liu et al., 2020; Liu et al., 2021). These results,
among others, show the vast potential stem cell therapy for OI holds.
It is important to note that stem cell treatment for OI comes with
limitations. These include amount of available stem cells, challenges
related to stem cell identification, isolation and purification, and po
tential immunological rejection by the host, all of which may influence
outcomes such as OI bone mechanical properties. Additionally, pre
conditioning irradiation treatment has been shown to increase osteo
clast number, deteriorate material properties of cortical bone, and
damage the bone marrow micro-environment for stem cells, implying
that irradiation is a major challenge to overcome in stem cell therapy
(Barth et al., 2011; Costa and Reagan, 2019; Willey et al., 2008; Cao
et al., 2011).
Future research should continue to explore how and why stem cell
therapy improves OI bone quality with the need to understand if these
therapies are actually addressing the brittleness in OI bone. The effects
of stem cell therapy on OI bone health in its totality must be explored
through investigations on the inter-relationship between the biological,
compositional, structural, and mechanical properties of bone (Fig. 3).
Multiscale and multidisciplinary studies in the future will need to assess
bone strength and fracture toughness, together to cell engraftment and
mechanisms of action, and use appropriate sham controls, to provide a
biological understanding of the mechanical changes that underlie the
shown decrease in fracture incidence. As the field moves forward,
standardization of research practices to conduct these studies must be
implemented. While qualitative histological data has shown the poten
tial of stem cell engraftment thus far, more quantitative results are
necessary to refine and distinguish the optimal therapeutic effects with
differing cell preparation and transplantation methods. Furthermore,
the use of histological sections to count the overall donor cell engraft
ment over the overall number of cells can over- or under-estimate the
engraftment as 2D slices of bone may not be representative of its entire
volume. Therefore, new effective protocols and methodologies need to
be developed for assessing and quantifying engraftment in the entire
bone. In this sense, the development of new biomarkers and quantitative
assays to predict the in-vivo efficacy of transplanted cells may greatly
help (Prockop, 2017). Investigation of bone cells (osteocytes, OBs and
osteoclasts) health, utilizing biomarkers of skeletal and cells cycle
regulation, as well as exploring their shape, will aid in the understanding
of the biological therapeutic effect of stem cells in OI bone. Moving
forward it is important that reagents used in the preparation and
culturing of stem cells be thoroughly defined in publications, as cells
have the potential to change dramatically in cultures with varying
conditions (Prockop, 2017). More studies are also needed to determine
the best route of injection, age of injection, or follow up time effect
outcomes, that were not possible to be established in this meta-analysis.
Finally, due to the nature of these basic science studies, variability and
lack of standardization of study characteristics were observed. This in
dicates the need for non-biased research techniques such as random
housing and blinded analyses to be utilized and thoroughly described in
the manuscripts reporting the stem cell studies (Hirst et al., 2014). These
must be explicitly indicated, and when not met, appropriately discussed
in the studies. Review-level limitations of this systematic review and
meta-analysis include the lack of variation in the use of mouse models of
OI included, as well as possible incomplete retrieval of all eligible
studies.
In conclusion, this systematic review and meta-analysis shows the
beneficial effects of stem cell therapy in mouse models of OI to reduce
fracture incidence and increase maximum load, besides a low cell
engraftment. This supports the need for further investigation of the
mechanisms by which transplanted stem cells affect bone (re)modeling
and bone quality. Particularly, being bone fragility the primary symp
tom of OI, there is a critical need to determine the fracture toughness of

OI bone treated with stem cells so to assess the actual efficacy of the
treatment to rescue OI bone brittleness.
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